Literature DB >> 17681742

Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts.

Xu Shi-Wen1, Elisabetta A Renzoni, Laura Kennedy, Sarah Howat, Yunliang Chen, Jeremy D Pearson, George Bou-Gharios, Michael R Dashwood, Roland M du Bois, Carol M Black, Christopher P Denton, David J Abraham, Andrew Leask.   

Abstract

Fibrosis is excessive scarring caused by the accumulation of extracellular matrix proteins and is a common end pathway in many chronic diseases. Endothelin-1 is a possible contributor to the persistent fibrotic phenotype of fibroblasts isolated from fibrotic lesions. In this report we used a specific dual endothelin A/B receptor antagonist, bosentan, to determine the role of endogenous endothelin signaling in maintaining the profibrotic phenotype of lung fibroblasts from scleroderma patients. Bosentan treatment of lung fibroblasts cultured from normal individuals and individuals with scleroderma was assessed using Affymetrix genome-wide expression profiling, real-time polymerase chain reaction and Western blot analysis and revealed that approximately one-third of the transcripts elevated greater than two-fold in fibrotic fibroblasts were reduced by Bosentan treatment. Genes whose overexpression in fibrotic fibroblasts that were dependent on endogenous endothelin signaling included the matrix or matrix-associated genes type I collagen, fibronectin and CCN2. The elevated adhesive property of fibrotic fibroblasts was also reduced by endothelin receptor antagonism. Basal expression of collagen, fibronectin and CCN2 and adhesion to matrix was not affected. Thus endogenous endothelin signaling contributes to the fibrotic phenotype of fibrotic fibroblasts, suggesting that antagonizing endothelin receptors may be of benefit in combating fibrotic disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17681742     DOI: 10.1016/j.matbio.2007.06.003

Source DB:  PubMed          Journal:  Matrix Biol        ISSN: 0945-053X            Impact factor:   11.583


  45 in total

1.  CCN-2 is up-regulated by and mediates effects of matrix bound advanced glycated end-products in human renal mesangial cells.

Authors:  Xiaoyu Wang; Susan V McLennan; Stephen M Twigg
Journal:  J Cell Commun Signal       Date:  2011-06-02       Impact factor: 5.782

2.  Survivin expression induced by endothelin-1 promotes myofibroblast resistance to apoptosis.

Authors:  Jeffrey C Horowitz; Iyabode O Ajayi; Priya Kulasekaran; David S Rogers; Joshua B White; Sarah K Townsend; Eric S White; Richard S Nho; Peter D R Higgins; Steven K Huang; Thomas H Sisson
Journal:  Int J Biochem Cell Biol       Date:  2011-10-25       Impact factor: 5.085

3.  Transforming growth factor-β regulates endothelin-1 signaling in the newborn mouse lung during hypoxia exposure.

Authors:  Nelida Olave; Teodora Nicola; Wei Zhang; Arlene Bulger; Masheika James; Suzanne Oparil; Yiu-Fai Chen; Namasivayam Ambalavanan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-01-27       Impact factor: 5.464

Review 4.  Recent advances in the treatment of systemic sclerosis.

Authors:  Vasiliki Kalliopi K Bournia; Panayiotis G Vlachoyiannopoulos; Carlo Selmi; Haralampos M Moutsopoulos; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

5.  1,25-dihydroxyvitamin d3 reduces extracellular matrix-associated protein expression in human uterine fibroid cells.

Authors:  Sunil K Halder; Kevin G Osteen; Ayman Al-Hendy
Journal:  Biol Reprod       Date:  2013-12-26       Impact factor: 4.285

6.  GSK-3beta in mouse fibroblasts controls wound healing and fibrosis through an endothelin-1-dependent mechanism.

Authors:  Mohit Kapoor; Shangxi Liu; Xu Shi-wen; Kun Huh; Matthew McCann; Christopher P Denton; James R Woodgett; David J Abraham; Andrew Leask
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

7.  Genome-wide DNA methylation analysis in dermal fibroblasts from patients with diffuse and limited systemic sclerosis reveals common and subset-specific DNA methylation aberrancies.

Authors:  Nezam Altorok; Pei-Suen Tsou; Patrick Coit; Dinesh Khanna; Amr H Sawalha
Journal:  Ann Rheum Dis       Date:  2014-05-08       Impact factor: 19.103

8.  A large multicentre analysis of CTGF -945 promoter polymorphism does not confirm association with systemic sclerosis susceptibility or phenotype.

Authors:  B Rueda; C Simeon; R Hesselstrand; A Herrick; J Worthington; N Ortego-Centeno; G Riemekasten; V Fonollosa; M C Vonk; F H J van den Hoogen; J Sanchez-Román; M A Aguirre-Zamorano; R García-Portales; A Pros; M T Camps; M A Gonzalez-Gay; M F Gonzalez-Escribano; M J Coenen; N Lambert; J L Nelson; T R D J Radstake; J Martin
Journal:  Ann Rheum Dis       Date:  2008-12-03       Impact factor: 19.103

9.  Rac inhibition reverses the phenotype of fibrotic fibroblasts.

Authors:  Shi-wen Xu; Shangxi Liu; Mark Eastwood; Sonali Sonnylal; Christopher P Denton; David J Abraham; Andrew Leask
Journal:  PLoS One       Date:  2009-10-13       Impact factor: 3.240

10.  Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease?

Authors:  Andrew Leask; Sunil K Parapuram; Xu Shi-Wen; D J Abraham
Journal:  J Cell Commun Signal       Date:  2009-01-21       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.